Cabergoline

Introduction to Cabergoline and Mechanism of Action in Lactation

Cabergoline is a long-acting dopamine receptor agonist derived from ergot. In the context of postpartum care, it is used primarily to stop breast milk production when a mother cannot or chooses not to breastfeed.

Prolactin is the main hormone responsible for milk synthesis in the mammary glands. Dopamine acts as the body's natural prolactin-inhibiting factor. By stimulating dopamine receptors in the anterior pituitary gland, cabergoline mimics this inhibitory action, causing a significant and prolonged drop in serum prolactin levels. Because of its high affinity for dopamine D2 receptors and its slow elimination from the body, a single oral dose is often sufficient to achieve complete and lasting suppression of lactation.

Clinical Indications for Lactation Suppression

Lactation suppression is indicated in situations where breastfeeding is medically discouraged, unsafe for the infant, or culturally or personally declined by the mother following delivery or pregnancy loss.

• Neonatal conditions: Infant metabolic disorders that prevent milk digestion, or severe congenital anomalies.
• Maternal infectious diseases: Active maternal infections such as untreated HIV or certain viral illnesses that can be transmitted through breast milk.
• Pregnancy loss: Stillbirth, neonatal death, or therapeutic termination of pregnancy where preventing breast engorgement provides physical and psychological relief.
• Maternal health choices: Personal or social decisions where the mother elects not to initiate breastfeeding.

Dosage, Administration, and Timing Protocols

To successfully prevent the onset of lactation after childbirth, timing is strict. Cabergoline must be administered as a single dose within the first twenty-four hours following delivery.

The standard adult therapeutic dose for preventing milk production is 1 mg given orally as a single dose. Because the drug has a long half-life, dividing this dose is unnecessary. For women who have already established lactation and wish to suppress it later, a different dosing schedule of 0.25 mg every twelve hours for two days is typically prescribed to gradually reduce existing milk volumes.

Common and Serious Side Effects

While generally well tolerated when given as a single dose, cabergoline can cause several adverse effects related to its dopaminergic and vascular actions.

Postural hypotension is particularly important in postpartum mothers who may already be weak from blood loss during delivery. Midwives should advise patients to rise slowly from a bed or chair to prevent fainting spells.

Contraindications and Maternal Precautions

Cabergoline is not safe for every patient. Thorough clinical screening before administration prevents severe complications.

• Pregnancy-induced hypertension: Women with disorders like pre-eclampsia or eclampsia should generally avoid cabergoline because it can worsen blood pressure instability.
• History of cardiovascular disease: The drug can affect vascular tone and is risky for women with unmanaged heart conditions.
• Hypersensitivity: Anyone with a known allergy to ergot derivatives must not take this medication.
• Psychiatric history: Use with extreme caution in patients with severe psychotic disorders, as dopamine agonists can exacerbate mental health symptoms.

Midwifery Nursing Care and Patient Counseling

Comprehensive midwifery care ensures the safe administration of cabergoline and supports the mother through both physical and emotional adjustments.

Before giving the medication, verify the client's identity, confirm her informed consent and choice regarding lactation, and check for any history of high blood pressure or liver disease. Monitor vital signs, especially blood pressure, for several hours post-administration.

Counsel the mother on non-pharmacological comfort measures for breast engorgement, such as wearing a supportive, snug-fitting bra, applying cold compresses, and avoiding breast stimulation or manual expression, which can stimulate further milk production.